ECSP13013095A - Composición farmacéutica que comprende fexofenadina - Google Patents

Composición farmacéutica que comprende fexofenadina

Info

Publication number
ECSP13013095A
ECSP13013095A ECSP13013095A ECSP13013095A EC SP13013095 A ECSP13013095 A EC SP13013095A EC SP13013095 A ECSP13013095 A EC SP13013095A EC SP13013095 A ECSP13013095 A EC SP13013095A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
fexofenadine
preparation
pharmaceutical formulation
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Praveen Khullar
Nilesh Jaiswal
Sudhakara Rao Badabhagni
Kum Prasad
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP13013095A publication Critical patent/ECSP13013095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica de hidrocloruro de fexofenadina en un sistema de disolvente adecuada como una composición líquida de relleno.En otro aspecto, la invención también se refiere a un proceso para la preparación de dicha formulación farmacéutica y al uso de dicha composición para la preparación de un fármaco para el tratamiento de reacciones alérgicas en un paciente.
ECSP13013095 2011-05-20 2013-12-19 Composición farmacéutica que comprende fexofenadina ECSP13013095A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1727CH2011 2011-05-20
US201161499856P 2011-06-22 2011-06-22
EP11305923 2011-07-13

Publications (1)

Publication Number Publication Date
ECSP13013095A true ECSP13013095A (es) 2014-01-31

Family

ID=47216626

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013095 ECSP13013095A (es) 2011-05-20 2013-12-19 Composición farmacéutica que comprende fexofenadina

Country Status (18)

Country Link
US (1) US20140073670A1 (es)
EP (1) EP2709600A1 (es)
JP (1) JP2014513708A (es)
KR (1) KR20140037876A (es)
CN (1) CN103687592A (es)
AR (1) AR086491A1 (es)
BR (1) BR112013029778A2 (es)
CA (1) CA2835912A1 (es)
CO (1) CO6831986A2 (es)
CR (1) CR20130591A (es)
EA (1) EA201391742A1 (es)
EC (1) ECSP13013095A (es)
IL (1) IL229417A0 (es)
MA (1) MA35400B1 (es)
MX (1) MX2013013575A (es)
SG (1) SG195015A1 (es)
UY (1) UY34080A (es)
WO (1) WO2012159960A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003109A1 (en) * 2013-07-03 2015-01-08 R.P. Scherer Technologies, Llc Capsule formulation comprising fexofenadine
US9504656B2 (en) * 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
CN104133014B (zh) * 2014-07-16 2015-09-16 广州法尔麦兰药物技术有限公司 一种考察布洛伪麻缓释制剂释放度的方法
CN107847496A (zh) * 2015-02-20 2018-03-27 英仕柏集团有限责任公司 含有非索非那丁的软明胶胶囊

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929605A (en) 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US6316473B1 (en) * 1997-04-11 2001-11-13 Fujisawa Pharmaceutical Co., Ltd. Two surfactant-containing medicinal composition
ID24463A (id) 1997-08-14 2000-07-20 Hoechst Marion Roussel Inc Metode meningkatkan ketersediaan hayati feksofenadin dan turunan-turunannya
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2001244610A1 (en) * 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
EP1455753A1 (en) * 2001-12-20 2004-09-15 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
CA2524773C (en) * 2003-05-08 2014-04-08 Nektar Therapeutics Uk Ltd Particulate coformulations of active substances with excipients
JP2005075804A (ja) * 2003-09-03 2005-03-24 Toyo Capsule Kk メナテトレノン含有医薬組成物
WO2005062722A2 (en) * 2003-11-21 2005-07-14 Sun Pharmaceutical Industries Limited Fexofenadine containing pharmaceutical formulation

Also Published As

Publication number Publication date
CO6831986A2 (es) 2014-01-10
JP2014513708A (ja) 2014-06-05
AR086491A1 (es) 2013-12-18
BR112013029778A2 (pt) 2017-01-17
MA35400B1 (fr) 2014-09-01
WO2012159960A1 (en) 2012-11-29
MX2013013575A (es) 2014-09-15
CN103687592A (zh) 2014-03-26
KR20140037876A (ko) 2014-03-27
US20140073670A1 (en) 2014-03-13
EA201391742A1 (ru) 2014-04-30
CR20130591A (es) 2014-05-07
CA2835912A1 (en) 2012-11-29
SG195015A1 (en) 2013-12-30
UY34080A (es) 2013-01-03
IL229417A0 (en) 2014-01-30
EP2709600A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
CR20150326A (es) Inhibidores de autotaxina
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
CO6710926A2 (es) Compuestos de n-heteroarilo
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
CL2014001704A1 (es) Derivados de amida ciclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa; composicion farmaceutica que los comprende y el uso de los mismos en la prevencion o tratamiento de enfermedades tales como la diabetes.
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015030431A2 (pt) formulação de liberação modificada
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
BR112013029790A2 (pt) composição farmacêutica compreendendo cetoprofeno
NI201300120A (es) Composición farmacéutica que comprende fexofenadina
ES2403130R1 (es) Forma polimorfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparacion
EP2668952A3 (en) Aqueous formulations of bisphosphonates, vitamin D and benzyl alcohol suitable for subcutaneous or intramuscular use